ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug DeliverySOLANA BEACH, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (
NASDAQ: CLPT) a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has entered into a multi-year license agreement with UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical leader, to partner on drug delivery platforms for UCB’s gene therapy portfolio.
